share_log

藥明康德：海外監管公告

WUXI APPTEC: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 18 10:30
Summary by Moomoo AI
药明康德於2024年3月18日發布了2023年度董事會審計委員會履職報告。報告指出，審計委員會成員於2023年5月31日經年度股東大會選舉產生，並於6月6日召開第一次會議。審計委員會在報告期內共召開5次會議，審議了財務報告、利潤分配方案等重要事項。委員會對公司及集團的財務報告進行了審核，確認報告真實、完整且準確，並對外部審計機構德勤的工作給予了正面評價。此外，審計委員會對公司內控制度建設、持續性關聯交易及募集資金使用情況進行了監督和評估，認為公司的內控運作符合上市公司治理規範的要求。報告總結表示，審計委員會將繼續恪守職責，以獨立、客觀、公正的態度履行職責。
药明康德於2024年3月18日發布了2023年度董事會審計委員會履職報告。報告指出，審計委員會成員於2023年5月31日經年度股東大會選舉產生，並於6月6日召開第一次會議。審計委員會在報告期內共召開5次會議，審議了財務報告、利潤分配方案等重要事項。委員會對公司及集團的財務報告進行了審核，確認報告真實、完整且準確，並對外部審計機構德勤的工作給予了正面評價。此外，審計委員會對公司內控制度建設、持續性關聯交易及募集資金使用情況進行了監督和評估，認為公司的內控運作符合上市公司治理規範的要求。報告總結表示，審計委員會將繼續恪守職責，以獨立、客觀、公正的態度履行職責。
Ming Kand Pharmaceuticals issued the 2023 Board Audit Committee Resume Report on 18 March 2024. The report noted that the members of the Audit Committee were elected at the Annual General Meeting on 31 May 2023 and held its first meeting on 6 June. The Audit Committee held a total of five meetings during the reporting period to examine important matters such as financial statements, profit distribution schemes. The Committee audited the financial statements of the company and the group, confirming that the reports were true, complete and accurate, and gave a positive assessment of the diligent work of external auditors. IN ADDITION, THE AUDIT COMMITTEE MONITORED AND EVALUATED THE INTERNAL CONTROL BUILDING, ONGOING ASSOCIATED TRANSACTIONS AND THE USE OF RAISING FUNDS, AND CONCLUDED THAT THE COMPANY'S INTERNAL CONTROL OPERATIONS WERE IN COMPLIANCE WITH THE GOVERNANCE REGULATIONS OF A LISTED COMPANY. The report concludes that the Audit Committee will continue to exercise its duties in an independent, objective and fair manner.
Ming Kand Pharmaceuticals issued the 2023 Board Audit Committee Resume Report on 18 March 2024. The report noted that the members of the Audit Committee were elected at the Annual General Meeting on 31 May 2023 and held its first meeting on 6 June. The Audit Committee held a total of five meetings during the reporting period to examine important matters such as financial statements, profit distribution schemes. The Committee audited the financial statements of the company and the group, confirming that the reports were true, complete and accurate, and gave a positive assessment of the diligent work of external auditors. IN ADDITION, THE AUDIT COMMITTEE MONITORED AND EVALUATED THE INTERNAL CONTROL BUILDING, ONGOING ASSOCIATED TRANSACTIONS AND THE USE OF RAISING FUNDS, AND CONCLUDED THAT THE COMPANY'S INTERNAL CONTROL OPERATIONS WERE IN COMPLIANCE WITH THE GOVERNANCE REGULATIONS OF A LISTED COMPANY. The report concludes that the Audit Committee will continue to exercise its duties in an independent, objective and fair manner.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more